Bicycle Therapeutics Q2 EPS $(1.41) Misses $(1.29) Estimate, Sales $11.40M Beat $4.58M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bicycle Therapeutics (NASDAQ:BCYC) reported Q2 losses of $(1.41) per share, missing the analyst consensus estimate of $(1.29) by 9.3%. This is a 56.67% decrease over losses of $(0.90) per share from the same period last year. However, the company reported quarterly sales of $11.40 million, beating the analyst consensus estimate of $4.58 million by 148.84%. This is a 160.32% increase over sales of $4.38 million the same period last year.
August 04, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bicycle Therapeutics reported a larger than expected loss for Q2, but significantly beat sales estimates.
While the company reported a larger than expected loss, the significant beat on sales could offset the negative impact of the earnings miss in the short term. The overall impact on the stock price is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100